Skip to content

Drug interactions

Liposomal doxorubicin + Ritonavir

Severity: Moderate

Liposomal doxorubicin and Ritonavir: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Ritonavir inhibits CYP3A4 and P-glycoprotein and may increase doxorubicin exposure, raising the risk of myelosuppression, mucositis and cardiotoxicity. The effect with the liposomal form is not well defined.

What this interaction means in plain words

Liposomal doxorubicin and Ritonavir can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Liposomal doxorubicin belongs to Oncology; Ritonavir belongs to Anti Virals.

Evidence level: Low

Why it happens

Ritonavir inhibits CYP3A4 and P-gp, reducing doxorubicin metabolism and efflux.

What to do

Monitor blood counts and signs of mucositis, palmar-plantar erythrodysesthesia and cardiac toxicity. Consider dose reduction if toxicity develops.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Liposomal doxorubicin and Ritonavir, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 7 days on the web. No card needed.

Frequently asked questions

Can I take Liposomal doxorubicin with Ritonavir?

MediHelp rates the interaction as moderate. Liposomal doxorubicin and Ritonavir can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Ritonavir inhibits CYP3A4 and P-glycoprotein and may increase doxorubicin exposure, raising the risk of myelosuppression, mucositis and cardiotoxicity. The effect with the liposomal form is not well defined.

How serious is the interaction between Liposomal doxorubicin and Ritonavir?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood counts and signs of mucositis, palmar-plantar erythrodysesthesia and cardiac toxicity. Consider dose reduction if toxicity develops.

What other medicines interact with Liposomal doxorubicin?

MediHelp also lists interactions of Liposomal doxorubicin with, for example, Dengue vaccine, Belatacept, Cyclosporine. The full list is on the Liposomal doxorubicin page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in